Results 161 to 170 of about 6,030,936 (310)

Atmospheric mercury monitoring data across Italy: A multi-year national dataset (2020 - 2023). [PDF]

Data Brief
Bencardino M, Tassone A, Martino M, D'Amore F, Sprovieri T, Ungaro C, Andreoli V, Esposito G, Siliprandi G, Lanzani G, Angiuli L, Nocioni A, Leonardi C, Sprovieri F, Pirrone N.   +14 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Twenty years (2000-2020) of butterfly monitoring data across the contiguous United States. [PDF]

Sci Data
Henry EH, Edwards CB, Shirey V, Pippen JS, Waetjen D, Forister ML, Larsen EA, Schultz CB, Michielini J, Brockman N, Burls KJ, Drum RG, Gatch M, Glassberg J, Hamlett NV, Hershcovich S, Le C, McGaffin S, Meilinger J, Richter L, Rochefort R, Schelz C, Shapiro AM, Sullivan K, Taron DJ, Thogmartin WE, Walker A, Westphal A, Wiedmann J, Wilcockson IU, Zaspel J, Ries L.   +31 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Natural Language Processing for Automated Extraction of Continuous Glucose Monitoring Data. [PDF]

Diabetes Care
Zheng Y, Song Y, Iturrate E, Wu B, Zweig S, Johnson SB.   +5 more
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Long-term biodiversity monitoring data from two hydroelectric dam projects in northeast Portugal, 2006-2023. [PDF]

Sci Data
Múrias T, Figueira R, Madeira J, Bertoluci V, Beja P.   +4 more
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Adding arterial nitrogen pressure to single-measurement monitoring data enables diagnostic lung modeling by deep learning. [PDF]

Physiol Rep
Scott PH, Anstey CM, Morgan TJ.
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source